NCT06416865CompletedPhase 3
Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of AJU-C52 in Compared With C52R1M for Essential Hypertension Patients in Inappropriately Controlled on C52R1L Treatment
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
A Randomized, Double-blind, Multi-center, Phase III study to evaluate the efficacy and safety of the AJU-C52 compared with the combination of C52R1M in patients with essential Hypertension Patients who have inappropriately controlled on C52R1L treament
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 193 (actual)
- First submitted
- 12 May 2024
- Start date
- 18 Oct 2022
- Primary completion date
- 23 Dec 2024
- Lead sponsor
- AJU Pharm Co., Ltd.
- Diseases
- High blood pressure
- NCT number
- NCT06416865
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 193
- From 18 Oct 2022 to the primary completion date, 23 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Secondary hypertension patients or those with a history of suspected secondary hypertension
- Cardiovascular/cerebrovascular disease
- Those with a history of malignant tumor within 5 years
Other
- At the screening visit (Visit 1), patients had 3 blood pressure measurements in the arm with the higher average MSSBP, those whose maximum and minimum blood pressure differences are MSSBP 20 mmHg and MSDBP 10 mmHg
Who the study is looking for
- Adults aged ≤19 years.
- Those who voluntarily signed the informed consent to participate in this study.
- A patient diagnosed with essential hypertension or Patients taking hypertension medication
- Those who are eligible for adequate blood pressure criteria during screening tests: Naïve patient-160 mmHg≤MSSBP\<200 mmHg and MSDBP\<110 mmHg/Patients taking hypertension medication-140 mmHg≤MSSBP\<200 mmHg and MSDBP\<110 mmHg
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| AJU Pharm Co., Ltd. Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
Related publications
- Efficacy and Safety of a Single-Pill Triple Combination of Valsartan, Amlodipine, and Chlorthalidone in Patients With Essential Hypertension Inadequately Controlled on Dual Therapy With Valsartan and Amlodipine: A Randomized, Double-Blind, Multicenter, Phase 3 Trial.J Clin Hypertens (Greenwich) · 2026 · PMID 42723352
This page is information, not medical advice. Discuss any trial with your doctor.